Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camizestrant pre-surgical biological effects study in breast cancer
NCT04588298Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2020
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of camizestrant in breast cancer, sponsored by AstraZeneca. Started Nov 2020; status: completed.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04588298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04588298.